Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection.

Giersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse AW, Pollok JM, Petersen J, Dandri M, Lütgehetmann M.

J Hepatol. 2015 Aug;63(2):346-53. doi: 10.1016/j.jhep.2015.03.011. Epub 2015 Mar 17.

PMID:
25795587
2.

Protein-peptide arrays for detection of specific anti-hepatitis D virus (HDV) genotype 1, 6, and 8 antibodies among HDV-infected patients by surface plasmon resonance imaging.

Villiers MB, Cortay JC, Cortès S, Bloquel B, Brichler S, Brakha C, Kay A, Falah N, Zoulim F, Marquette C, Marche PN, Dény P.

J Clin Microbiol. 2015 Apr;53(4):1164-71. doi: 10.1128/JCM.03002-14. Epub 2015 Jan 28.

3.

Anti-HDV IgM as a marker of disease activity in hepatitis delta.

Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group.

PLoS One. 2014 Jul 29;9(7):e101002. doi: 10.1371/journal.pone.0101002. eCollection 2014.

4.
5.

Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals.

Lunemann S, Malone DF, Grabowski J, Port K, Béziat V, Bremer B, Malmberg KJ, Manns MP, Sandberg JK, Cornberg M, Ljunggren HG, Wedemeyer H, Björkström NK.

Gut. 2015 Mar;64(3):469-82. doi: 10.1136/gutjnl-2014-306767. Epub 2014 Apr 10.

PMID:
24721903
6.

Characterization of hepatitis delta virus in sub-Saharan Africa.

Andernach IE, Leiss LV, Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, Omilabu S, Gouandjika-Vasilache I, Komas NP, Mbah OP, Muller CP.

J Clin Microbiol. 2014 May;52(5):1629-36. doi: 10.1128/JCM.02297-13. Epub 2014 Mar 5.

7.

Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy.

Ieluzzi D, Covolo L, Donato F, Fattovich G.

Dig Liver Dis. 2014 May;46(5):427-32. doi: 10.1016/j.dld.2014.01.003. Epub 2014 Feb 16.

PMID:
24548819
8.

Serological and molecular diagnosis of hepatitis delta virus infection: results of a French national quality control study.

Brichler S, Le Gal F, Neri-Pinto F, Mansour W, Roulot D, Laperche S, Gordien E.

J Clin Microbiol. 2014 May;52(5):1694-7. doi: 10.1128/JCM.03521-13. Epub 2014 Feb 12.

9.

Mathematical models of the interrelated dynamics of hepatitis D and B.

Packer A, Forde J, Hews S, Kuang Y.

Math Biosci. 2014 Jan;247:38-46.

PMID:
24513247
10.

HBV life cycle is restricted in mouse hepatocytes expressing human NTCP.

Li H, Zhuang Q, Wang Y, Zhang T, Zhao J, Zhang Y, Zhang J, Lin Y, Yuan Q, Xia N, Han J.

Cell Mol Immunol. 2014 Mar;11(2):175-83. doi: 10.1038/cmi.2013.66. Epub 2014 Feb 10.

11.

Comparison of the histological and serological parameters of patients with hepatitis delta virus in active and inactive hepatitis B virus carriers.

Shaikh S, Ram DB, Tanveer S, Talpur A.

J Coll Physicians Surg Pak. 2014 Feb;24(2):97-100. doi: 02.2014/JCPSP.97100.

PMID:
24491002
12.

No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance.

Visco-Comandini U, Lapa D, Taibi C, Angeletti C, Capobianchi MR, Garbuglia AR.

Dig Liver Dis. 2014 Apr;46(4):348-52. doi: 10.1016/j.dld.2013.11.006. Epub 2013 Dec 31.

PMID:
24387833
13.

High prevalence and significance of hepatitis D virus infection among treatment-naïve HBsAg-positive patients in Northern Vietnam.

Sy BT, Ratsch BA, Toan NL, Song le H, Wollboldt C, Bryniok A, Nguyen HM, Luong HV, Velavan TP, Wedemeyer H, Kremsner PG, Bock CT.

PLoS One. 2013 Oct 18;8(10):e78094. doi: 10.1371/journal.pone.0078094. eCollection 2013.

14.

Chronic hepatitis D at a standstill: where do we go from here?

Ciancio A, Rizzetto M.

Nat Rev Gastroenterol Hepatol. 2014 Jan;11(1):68-71. doi: 10.1038/nrgastro.2013.164. Epub 2013 Sep 10. Review.

PMID:
24019153
15.

High prevalence of hepatitis delta virus among patients with chronic hepatitis B virus infection and HIV-1 in an intermediate hepatitis B virus endemic region.

Saravanan S, Madhavan V, Velu V, Murugavel KG, Waldrop G, Solomon SS, Balakrishnan P, Kumarasamy N, Smith DM, Mayer KH, Solomon S, Thyagarajan SP.

J Int Assoc Provid AIDS Care. 2014 Jan-Feb;13(1):85-90. doi: 10.1177/2325957413488166. Epub 2013 May 30.

16.

Are patients with primary hepatocellular carcinoma infectious of hepatitis B, C and D viruses?

Olal SO, Akere A, Otegbayo JA, Odaibo GN, Olaleye DO, Afolabi NB, Bamgboye EA.

Afr J Med Med Sci. 2012 Dec;41 Suppl:187-91.

PMID:
23678655
17.

A re-assessment of the epidemiology and patient characteristics of hepatitis D virus infection in inner city London.

William Tong CY, Asher R, Toby M, Ngui SL, Tettmar K, Ijaz S, Tedder R, Kulasegaram R, Wilkinson M, Wong T.

J Infect. 2013 Jun;66(6):521-7. doi: 10.1016/j.jinf.2013.02.006. Epub 2013 Mar 4.

PMID:
23466596
18.

Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.

Ouzan D, Pénaranda G, Joly H, Halfon P.

J Hepatol. 2013 Jun;58(6):1258-9. doi: 10.1016/j.jhep.2012.12.019. Epub 2013 Jan 11. No abstract available.

19.

[Prevalence of seronegative hepatitis D among patients with chronic viral hepatitis B].

Semenov AV.

Zh Mikrobiol Epidemiol Immunobiol. 2012 Nov-Dec;(6):106-9. Russian.

PMID:
23297644
20.

[The analysis of hepatitis delta virus infective markers in the hepatitis is B virus infective people].

Xu PS, Han SY, Sun CY, Zhao J.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012 Aug;26(4):307-9. Chinese.

PMID:
23189853

Supplemental Content

Loading ...
Support Center